Abstract

Objective: To assess the effects of Metformin, Dichloroacetate (DCA) and their combination on cell viability in oral squamous cell carcinoma, UPCI-SCC-131 cell line.

Methods: UPCI-SCC-131 cells were plated in 96 E-plate (1x10^4 cells/well) and were treated with Metformin (1-16mM) and/or DCA (15-120mM) for 24-48-72h. xCELLigence SP system was used to monitor real time cell viability. In addition, drug combination index was analyzed with CompuSyn software according to Chou-Talalay method.

Results: Half-maximal inhibitory concentrations (IC_{50}) of Metformin and DCA were found to be 3mM and 23mM, respectively, for 72 hours. CI values (0.76-0.80) in all combination groups below 1 indicated that Metformin/DCA combination had a moderate synergistic effect on cell viability in UPCI-SCC-131 cells.

Discussion: Metformin/DCA combination synergistically decreased the cell viability of UPCI-SCC-131 cells. Therefore, a combined application of Metformin and DCA may be considered as a candidate therapy for the “drug repositioning” of the treatment of oral cavity cancer.

Keywords: Metformin, Dichloroacetate, drug combinations, oral cavity, cancer

Introduction

Oral squamous cell carcinoma (OSCC) is a predominant, aggressive and drug-resistant cancer type among head and neck cancers. Due to limitations of conventional therapy approaches; developing a novel and an effective therapeutic strategy is of utmost importance for the treatment of this cancer.

Metformin (1,1-dimethylbiguanide hydrochloride) is an antidiabetic agent which used in the treatment of Type 2 diabetes and inhibits mitochondrial Complex I also known as NADH/ubiquinone oxidoreductase. Currently, metformin has also found to be associated with improved survival in Type 2 diabetic patients with breast, prostate, colorectal, and head and neck cancer.[1] Several studies have reported that metformin had a synergistic effect on the efficacy of chemotherapeutic approaches in several tumors, therefore, has great potential as a neoadjuvant anti-cancer agent.[2,3]

Dichloroacetate (DCA), a small kinase inhibitor of pyruvate dehydrogenase kinase (PDK), promotes the flux
of carbohydrates into mitochondria through pyruvate dehydrogenase (PDH) activation. Dichloroacetate exerts anti-tumorigenic functions via inhibition of PDK leading to altered energy metabolism and increased cell death in many tumors, including pancreatic, breast, endometrial and ovarian cancers.\(^4\,^5\) In addition, in vitro studies have indicated that DCA sensitized metformin cytotoxicity by reprogramming of energy metabolism in cancer cells.\(^6\)

In the treatment of oral cavity cancer, new combination strategies that not only reduce cancer cell viability but also have low side effects are urgently required. Considering the therapeutic potential of metformin and DCA, the main objective of the study was to evaluate whether both of these drugs had a synergistic effect on the cell viability of UPCI-SCC-131 cells and contribute to combination therapy for the treatment of OSCC.

**Methods**

**Cell Culture**

UPCI-SCC-131 (Oral squamous cell carcinoma cell line), was purchased from DSMZ (Braunschweig, Germany). Cells were cultured in MEM supplemented with 10% fetal bovine serum (FBS) (Biochrom, Berlin, Germany), 1% non-essential amino acids (Thermo Fisher Scientific, Waltham, MA, USA), 2 mM L-Glutamine (Thermo Scientific, Waltham, MA, USA), and 100 units/mL penicillin/100 μg/mL streptomycin (Thermo Fisher Scientific, Waltham, MA, USA) at 37°C in 5% CO\(_2\) humidified incubator.

**Real Time Cell Viability Analysis**

UPCI-SCC-131 cells were seeded at 1x10\(^4\) cells/well into gold-coated 96 E-plate overnight and exposed to Metformin and DCA at various concentrations for 72 hours at 37°C. The cell viability was monitored by using Real-Time Cell Analyzer (RTCA) Single Plate (SP) (Roche Applied Science, Mannheim, Germany). The cell index value that represents cell viability was measured according to the relative change in electrical impedance, and also calculated by using the RTCA Software Version 2.0.

**Combination Index Calculation**

Drug combination was evaluated based on the principle of Chou and Talalay\(^7\) which is used in the calculation of the inhibitory effect (Fa), dose reduction index (DRI), and effect of Metformin and DCA. The synergistic effects of the combined treatments were analyzed with CompuSyn version 1.0 software (ComboSyn, Inc., Paramus, NJ, USA). CI values <1 indicate synergism, CI values=1 are additive and CI values >1 shows antagonism. In addition, DRI values above 1 imply a favorable dose reduction in the drug combination compared to the monotherapy.

**Statistical Analysis**

Half maximal inhibitory concentrations (IC\(_{50}\)) of Metformin and DCA were determined by GraphPad Prism 7.0 (San Diego, CA, USA). All data were represented as means ± standard error (SEM). Group comparisons were evaluated using Two-way ANOVA test with Dunnett’s Post Hoc test. * p≤0.05; **** p≤0.0001 were defined as statistically significant.

**Results**

**Cell viability and IC\(_{50}\) values in Metformin and DCA treated UPCI-SCC-131 cells**

The xCELLigence RTCA SP system monitors the real-time cell viability through determination of cell impedance which is expressed as cell index. Figure 1A and Figure 2A represent the time-dependent effects of Metformin and DCA on UPCI-SCC-131 cell index, respectively. While all treated doses of Metformin had no inhibitory effect on cell viability for 24 and 48 hours, we found a dose-dependent reduction with an IC\(_{50}\) of 3mM in UPCI-SCC-131 cells for 72 hours (Figure 1B).

In contrast to Metformin, DCA significantly decreased the cell viability in a dose- and a time-dependent manner. The IC\(_{50}\) value of DCA for 72 hours was 23mM in UPCI-SCC-131 cells (Figure 2B).

**The evaluation of Drug Synergism**

The combination of Metformin and DCA was assessed according to Chou-Talalay method. Two drugs were combined in a constant ratio (1:60) to calculate CI and DRI values using CompuSyn software. As shown in Table 1, inhibitory effect (Fa) values of 0.05, 0.5, 0.75, 0.90, 0.95, and 0.097 were used to determine CI and DRI values. All CI values ranged from 0.76 to 0.81 that indicate the combination of Metformin and DCA had a moderate synergistic effect against OSCC cell viability (Figure 3A and 3B). We also found that all DRI values were above “1” which allows favorable dose reduction either Metformin or DCA
Table 1. Inhibitory Effect (Fa), Dose Reduction Index (DRI), and Combination Index (CI) that belong to Metformin and DCA combination in UPCI-SCC-131 cells.

<table>
<thead>
<tr>
<th>Inhibitory Effect (Fa)</th>
<th>Combination Index (CI)</th>
<th>Dose Metformin (mM)</th>
<th>Dose DCA (mM)</th>
<th>Dose Reduction Index (DRI) Metformin</th>
<th>Dose Reduction Index (DRI) DCA</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.05</td>
<td>0.76708</td>
<td>0.77904</td>
<td>7.97766</td>
<td>8.94194</td>
<td>1.52614</td>
</tr>
<tr>
<td>0.5</td>
<td>0.78211</td>
<td>3.15865</td>
<td>23.4912</td>
<td>11.5938</td>
<td>1.43707</td>
</tr>
<tr>
<td>0.75</td>
<td>0.78994</td>
<td>5.32516</td>
<td>35.1484</td>
<td>12.7735</td>
<td>1.40519</td>
</tr>
<tr>
<td>0.90</td>
<td>0.79885</td>
<td>8.97766</td>
<td>52.5905</td>
<td>14.0733</td>
<td>1.37401</td>
</tr>
<tr>
<td>0.95</td>
<td>0.80551</td>
<td>12.8068</td>
<td>69.1725</td>
<td>15.0321</td>
<td>1.35320</td>
</tr>
<tr>
<td>0.97</td>
<td>0.81053</td>
<td>16.4897</td>
<td>84.0666</td>
<td>15.7539</td>
<td>1.33859</td>
</tr>
</tbody>
</table>

Figure 1. Cell index values and percentage of cell viability of Metformin-treated UPCI-SCC-131 cells. A) Dose-response curve of cell index was analyzed using the xCELLigence RTCA SP system. Cells were exposed to MEM (black), 1mM (red), 2mM (green), 4mM (blue), 8mM (pink), and 16mM (light blue) Metformin for 72 hours. B) The percentage of cell viability was calculated by using cell index values in Metformin-treated UPCI-SCC-131 cells for 24, 48 and 72 hours. Data are expressed as mean ± SEM (n=3). * p ≤ 0.05; **** p ≤ 0.0001
Oral squamous cell carcinoma is the sixth most common cancer and increasing rapidly worldwide. The current conventional strategies for the treatment of OSSC include surgical resection, radiotherapy and/or cisplatin based chemotherapy. Even though these multimodal strategies are effective for early stage-oral cavity cancer, 5-years survival rates are significantly lower for the patients with advanced stage-oral squamous cell carcinoma. Therefore, new FDA-approved drugs that lead to cytotoxicity in oral cavity cell carcinoma are needed to be addressed. In oncology, “drug repositioning” defines re-investigating the FDA-approved drugs for new therapeutic options particularly for cancer patients; thereby providing drug discovery that has minimal and known side effects, good bioavailability and low cost.

Recent studies have showed that the anti-diabetic drug, Metformin, inhibited the cell proliferation and induced cell death in several human cancers such as prostate cancer.
breast cancer,\textsuperscript{[11]} and OSCC.\textsuperscript{[12]} Moreover, metformin has a synergistic antitumor effect when used in combination with other well-known chemotherapeutic agents such as cisplatin, 5-fluorourasil, and paclitaxel.\textsuperscript{[13-15]}

Dichloroacetate is widely used in the treatment of lactic acidosis, inhibits pyruvate dehydrogenase kinase (PDK) via phosphorylation of pyruvate dehydrogenase. It is reported that PDK-1 inhibition by DCA reversed Warburg effect, and this leads to a decreased cancer malignancy. Because of this role, DCA is a promising drug in the treatment of various cancers.\textsuperscript{[16]}

In the current study, we investigated the effects of Metformin and DCA alone on cell viability and the potential of their combination against UPCI-SCC-131 cells. Our results reveal that Metformin and DCA inhibited the cell viability in time- and dose-dependent manner with an IC\textsubscript{50} of 3 and 23mM, respectively. The synergistic inhibition effects of Metformin and DCA which was analyzed with CompuSyn method, showed moderate synergism on cell viability of OSCC cells (CI < 1). Similarly Li et al., reported that DCA and Metformin combination could inhibit the cell viability to as low as 50% in ovarian cancer cells.\textsuperscript{[17]} It is also demonstrated that the combination of DCA and Metformin synergistically induce apoptosis via oxidative damage in breast cancer cells.\textsuperscript{[18,19]} Florio et al reported that both Metformin and DCA reduced cell viability in auton-

\begin{figure}[h]
\centering
\includegraphics[width=\textwidth]{figure3.png}
\caption{The combined effects of Metformin and DCA analyzed with CompuSyn system. A) Combination Index Plot (Fa-CI plot) B) Logarithmic Combination Index Plot (Log(CI)-Fa) C) Dose Reduction Index Plot (Fa-DRI plot), and D) Logarithmic Dose Reduction Index Plot (Log(DRI)-Fa). Met; Metformin.}
\end{figure}
onomic nervous system tumors, paragangliomas. In addition, DCA/Metformin/GW6471 combination showed strong synergistic effects on cell viability and clonogenic ability.\[20\]

The combination of drugs used in cancer therapy is expected to exhibit antitumorigenic behavior. In this regard, our results suggest that the potential use of metformin and DCA combination as an anticancer agent may be a promising therapeutic strategy for the treatment of oral cavity cancers. However, further experimental and clinical studies are required.

References